Go Pro
→ Gates. Google. The Pentagon. (From Behind the Markets) (Ad)tc pixel
NASDAQ:WGS

GeneDx Q2 2026 Earnings Report

GeneDx logo
$63.85 -1.79 (-2.73%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$62.65 -1.20 (-1.89%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

GeneDx EPS Results

Actual EPS
N/A
Consensus EPS
-$0.19
Beat/Miss
N/A
One Year Ago EPS
N/A

GeneDx Revenue Results

Actual Revenue
N/A
Expected Revenue
$111.01 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

GeneDx Announcement Details

Quarter
Q2 2026
Date
8/4/2026
Time
Before Market Opens
Conference Call Date
Tuesday, July 28, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

GeneDx Earnings Headlines

Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm
July 13 at 6:55 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326535/0/en/bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-been-filed-against-genedx-holdings-corp-and-encourages-investors-to-contact-the-firm.html
HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge
July 13 at 6:10 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326519/32716/en/hbss-investigates-claims-against-genedx-holdings-wgs-in-securities-class-action-suit-following-massive-impairment-charge.html
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.tc pixel
July 14 at 1:00 AM  |  Brownstone Research (Ad)
Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 3, 2026 - WGS
July 13 at 10:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326286/3080/en/levi-korsinsky-reminds-genedx-holdings-corp-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-3-2026-wgs.html
GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGS
July 13 at 4:57 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genedx-holdings-corp-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--wgs-302823618.html
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
July 13 at 4:43 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/wgs-investors-have-opportunity-to-lead-genedx-holdings-corp-securities-fraud-lawsuit-with-the-schall-law-firm-302823609.html
See More GeneDx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GeneDx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeneDx and other key companies, straight to your email.

About GeneDx

GeneDx (NASDAQ:WGS) is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care. In 2015, the company became a subsidiary of OPKO Health, leveraging OPKO’s global infrastructure to expand its testing capabilities and research collaborations. GeneDx holds College of American Pathologists (CAP) accreditation and is CLIA-certified, ensuring adherence to stringent quality and regulatory standards.

GeneDx serves a diverse client base that includes hospitals, academic medical centers, reference laboratories and pharmaceutical partners, as well as patients participating in research studies. While its primary market is the United States, the company also accommodates international referrals through its global network, enabling access to advanced genetic diagnostics for clinicians and patients worldwide. With a dedicated team of geneticists, laboratory scientists and genetic counselors, GeneDx continues to advance precision medicine by translating complex genomic data into actionable clinical insights.

View GeneDx Profile
Earnings Tools